Animal studies were performed in strict accordance with the regulations of the Johns Hopkins Animal Care and Use Committee and Omeros’ Animal Care and Use Committee. NOD.Cg-PrkdcscidIL-2rgtm1Wjl/SzJ mice (NSG) (the Jackson Laboratory, Bar Harbor, ME, USA) mice were injected either intravenously or subcutaneously with CD19+ Nalm6 tumor cells (DSMZ, Braunschweig, Germany) that were engineered as per the manufacturer’s protocol to express enhanced green fluorescent protein (eGFP) and fLuc (PerkinElmer, Hopkinton, MA, USA) (Nalm6-eGFP-fLuc). In the Nalm6 intravenously administered model, tumor engraftment was allowed to occur for 4 days and verified using BLI. On day 4, mice received a single intravenous injection of mock, CD19-EGFRt, or CD19-tPSMA(N9del) CAR T cells. In the Nalm6 subcutaneously disseminated model, spontaneous metastatic lesions develop. Tumor engraftment was verified using BLI. On day 21 after tumor implantation, mice received a single intravenous injection of mock, CD19-EGFRt, or CD19-tPSMA(N9del) CAR T cells.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.